Supernus Q2 earnings rise 32%, raises guidance
Supernus Pharmaceuticals reported a strong revenue increase, raising its full-year guidance and agreeing to merge with Indivior to enhance its CNS portfolio.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day